SP1 and breast carcinoma: Earlier, we reported that 2-Tellurium-bridged b-cyclodextrin (2-TeCD), one of TrxR inhibitors, could sensitize TRAIL-resistant human breast cancer cells and xenograft tumors to undergo apoptosis via Sp1-mediated DR5 up-regulation.